Skip to main content

Advertisement

Figure 2 | Arthritis Research & Therapy

Figure 2

From: Synovial membrane immunohistology in early-untreated rheumatoid arthritis reveals high expression of catabolic bone markers that is modulated by methotrexate

Figure 2

Methotrexate decreases expression of RANKL and RANK in the rheumatoid synovium of early-untreated rheumatoid arthritis. Brown immunohistochemistry (diaminobenzidine) staining of cell surface markers in synovial biopsies of early rheumatoid arthritis (RA). Synovial receptor activator of the NF-κB ligand (RANKL) expression in early, untreated RA synovium (A) decreased significantly following 8 weeks of methotrexate (MTX) treatment (B), as evaluated by semi-quantitative double-blind microscopic analysis (C). Synovial receptor activator of NF-κB (RANK) expression in early, untreated RA synovium (D) decreased significantly following 8 weeks of MTX treatment (E), as evaluated by semi-quantitative double-blind microscopic analysis (F). Synovial osteoprotegerin (OPG) expression in early, untreated RA (G) is not changed following 8 weeks (H) of MTX treatment, as evaluated by semi-quantitative double-blind microscopic analysis (I). *p<0.05.

Back to article page